HRT Financial LLC lessened its holdings in Inogen Inc (NASDAQ:INGN) by 15.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,050 shares of the medical technology company’s stock after selling 553 shares during the quarter. HRT Financial LLC’s holdings in Inogen were worth $378,000 as of its most recent SEC filing.
Several other hedge funds have also made changes to their positions in INGN. Sapphire Star Partners LP grew its stake in shares of Inogen by 1.9% in the fourth quarter. Sapphire Star Partners LP now owns 7,437 shares of the medical technology company’s stock valued at $924,000 after acquiring an additional 136 shares in the last quarter. Bowling Portfolio Management LLC acquired a new position in shares of Inogen in the fourth quarter valued at about $345,000. Malaga Cove Capital LLC acquired a new stake in Inogen during the fourth quarter worth about $576,000. Mackenzie Financial Corp acquired a new stake in Inogen during the fourth quarter worth about $2,506,000. Finally, Advisors Asset Management Inc. grew its stake in Inogen by 2,634.0% during the third quarter. Advisors Asset Management Inc. now owns 1,285 shares of the medical technology company’s stock worth $314,000 after buying an additional 1,238 shares in the last quarter. 98.63% of the stock is currently owned by institutional investors and hedge funds.
A number of brokerages have issued reports on INGN. Zacks Investment Research upgraded shares of Inogen from a “hold” rating to a “buy” rating and set a $169.00 price objective on the stock in a research note on Tuesday, February 5th. Needham & Company LLC reiterated a “strong-buy” rating and set a $191.00 price objective (down from $280.00) on shares of Inogen in a research note on Wednesday, February 27th. JPMorgan Chase & Co. reduced their price objective on shares of Inogen to $175.00 and set an “overweight” rating on the stock in a research note on Wednesday, February 27th. Piper Jaffray Companies reduced their price objective on shares of Inogen from $290.00 to $185.00 and set an “overweight” rating on the stock in a research note on Wednesday, February 27th. Finally, BidaskClub upgraded shares of Inogen from a “sell” rating to a “hold” rating in a research note on Monday, January 7th. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and five have assigned a buy rating to the company. The stock has an average rating of “Hold” and an average target price of $189.00.
Inogen (NASDAQ:INGN) last issued its quarterly earnings data on Tuesday, February 26th. The medical technology company reported $0.44 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.25 by $0.19. The business had revenue of $86.50 million during the quarter, compared to analyst estimates of $82.06 million. Inogen had a net margin of 14.48% and a return on equity of 18.60%. The firm’s quarterly revenue was up 35.6% on a year-over-year basis. During the same quarter last year, the business earned ($0.03) EPS. On average, equities analysts predict that Inogen Inc will post 1.91 earnings per share for the current fiscal year.
TRADEMARK VIOLATION WARNING: “HRT Financial LLC Has $378,000 Holdings in Inogen Inc (NASDAQ:INGN)” was first reported by Baseball Daily News and is owned by of Baseball Daily News. If you are reading this piece of content on another website, it was illegally copied and reposted in violation of U.S. & international copyright legislation. The original version of this piece of content can be accessed at https://www.baseballdailydigest.com/news/2019/04/21/inogen-inc-ingn-shares-sold-by-hrt-financial-llc.html.
Inogen, Inc, a medical technology company, primarily develops, manufactures, and markets portable oxygen concentrators for patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.
Read More: What is the quiet period?
Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.